Our top pick for
Acasti Pharma Inc is a biotechnology business based in the US. Acasti Pharma shares (ACST) are listed on the NASDAQ and all prices are listed in US Dollars. Acasti Pharma employs 32 staff and has a trailing 12-month revenue of around USD$81,000.
|52-week range||USD$0.18 - USD$1.22|
|50-day moving average||USD$0.8027|
|200-day moving average||USD$0.4224|
|Wall St. target price||USD$2.52|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.027|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Acasti Pharma stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Acasti Pharma's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Acasti Pharma's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 26x. In other words, Acasti Pharma shares trade at around 26x recent earnings.
That's comparable to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29).
|Gross profit TTM||USD$0|
|Return on assets TTM||-28.31%|
|Return on equity TTM||24.66%|
|Market capitalisation||USD$125.4 million|
TTM: trailing 12 months
There are currently 1.8 million Acasti Pharma shares held short by investors – that's known as Acasti Pharma's "short interest". This figure is 20.5% down from 2.2 million last month.
There are a few different ways that this level of interest in shorting Acasti Pharma shares can be evaluated.
Acasti Pharma's "short interest ratio" (SIR) is the quantity of Acasti Pharma shares currently shorted divided by the average quantity of Acasti Pharma shares traded daily (recently around 59.3 million). Acasti Pharma's SIR currently stands at 0.03. In other words for every 100,000 Acasti Pharma shares traded daily on the market, roughly 30 shares are currently held short.
However Acasti Pharma's short interest can also be evaluated against the total number of Acasti Pharma shares, or, against the total number of tradable Acasti Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Acasti Pharma's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Acasti Pharma shares in existence, roughly 10 shares are currently held short) or 0.0099% of the tradable shares (for every 100,000 tradable Acasti Pharma shares, roughly 10 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Acasti Pharma.
Find out more about how you can short Acasti Pharma stock.
We're not expecting Acasti Pharma to pay a dividend over the next 12 months.
Acasti Pharma's shares were split on a 1:10 basis on 15 October 2015. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Acasti Pharma shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Acasti Pharma shares which in turn could have impacted Acasti Pharma's share price.
Over the last 12 months, Acasti Pharma's shares have ranged in value from as little as $0.18 up to $1.22. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Acasti Pharma's is 1.5195. This would suggest that Acasti Pharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia; and TRILOGY that is in Phase III to evaluate the safety and efficacy of CaPre in patients with sHTG. The company was incorporated in 2002 and is headquartered in Laval, Canada.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
Everything we know about the ChargePoint IPO, plus information on how to buy in.
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
Everything we know about the Soho House IPO, plus information on how to buy in.
Everything we know about the VIZIO IPO, plus information on how to buy in.
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.